Patent 10525074 was granted and assigned to Epizyme on January, 2020 by the United States Patent and Trademark Office.
The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.